4
Oct

High up-front costs could delay access to life-saving blood cancer drugs for Medicare patients

In the study published in the Journal of Clinical Oncology, prescription UNC Lineberger researchers report that nearly a third of a group of patients with chronic myeloid leukemia, cialis and who have federally-funded Medicare health insurance, price did not start treatment within six months of diagnosis with any of three targeted drugs that have led to dramatic improvements in survival for the disease.

Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients’ treatment with a novel class of targeted therapies, according to a University of North Carolina Lineberger Comprehensive Cancer Center-led study.

In the study published in the Journal of Clinical Oncology, researchers report that nearly a third of a group of patients with chronic myeloid leukemia, and who have federally-funded Medicare health insurance, did not start treatment within six months of diagnosis with any of three targeted drugs that have led to dramatic improvements in survival for the disease. However, patients who had access to subsidies to help cover those drug costs had a shorter median time to starting the drugs.

Read Full Article Here >>